A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers-Reference-Cited by-同舟云学术

A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers

Published:2019-07-19 Issue:10 Volume:20 Page:
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Straube Christoph,Kessel Kerstin A.,Zimmer Claus,Schmidt-Graf Friederike,Schlegel Jürgen,Gempt Jens,Meyer Bernhard,Combs Stephanie E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11864-019-0673-y.pdf

Reference64 articles.

1. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401. https://doi.org/10.1016/S1470-2045(06)70665-9 .

2. Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1460–9. https://doi.org/10.1001/jamaoncol.2016.1373 .

3. Straube C, Schmidt-Graf F, Wiestler B, Zimmer C, Meyer B, Combs SE. The algorithms of adjuvant therapy in gliomas and their effect on survival. J Neurosurg Sci. 2018;63. https://doi.org/10.23736/S0390-5616.18.04610-6 .

4. Shapiro WR, Green SB, Burger PC, Mahaley MS, Selker RG, VanGilder JC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg. 1989;71:1–9. https://doi.org/10.3171/jns.1989.71.1.0001 .

5. van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;6736:1–9. https://doi.org/10.1016/S0140-6736(17)31442-3 .

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers;Journal of Neuro-Oncology;2024-03-23

2. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence;Clinical and Translational Radiation Oncology;2024-01

3. Own experience in treating patients with progression of anaplastic astrocytomas of the brain. Factors influencing survival;P.A. Herzen Journal of Oncology;2024

4. Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study;Journal of Korean Medical Science;2024

5. Recurrent Glioblastoma: A Review of the Treatment Options;Cancers;2023-08-26